

# Getting Your Patient Started

Prescribing XOLREMDI and enrolling your patient in X4Connect



**X4Connect**<sup>™</sup>

## INDICATION

XOLREMDI<sup>®</sup> (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Please see Important Safety Information on the last page and full [Prescribing Information](#).

# Submit the X4Connect Enrollment Form

## Help your patient enroll in 3 simple steps:

1

Download and complete the form for your patient



Download form

2

Invite your patient to review and sign the patient consent section so that they can receive support from X4Connect

3

Fax the completed form, along with required documentation, to X4Connect at 877-914-0598

### Dosing

- Patients weighing >50 kg: **400 mg** orally once daily
- Patients weighing ≤50 kg: **300 mg** orally once daily

### Prescribing XOLREMDI® (mavorixafor)

When completing the enrollment form, be sure to include front and back copies of the patient's medical and pharmacy insurance cards, and a list of their past and current medications.

XOLREMDI is available through PANTHERx, our exclusive specialty pharmacy partner. When you complete the X4Connect Enrollment Form, PANTHERx will verify coverage, and once approved, XOLREMDI will be shipped directly to your patient.

Clinicians who prefer to ePrescribe may do so by sending a prescription directly to PANTHERx. To give your patient access to the full suite of patient support services, including financial support, please also complete the X4Connect Enrollment Form.

To ePrescribe:



PANTHERx Specialty Pharmacy  
24 Summit Park Drive,  
Pittsburgh, PA 15275

NPI: 1316213531  
[www.pantherxrare.com](http://www.pantherxrare.com)  
T: (833) 711-8824

If ePrescribe is used, you still need to fax the X4Connect Enrollment Form along with the required documentation to 877-914-0598.

**X4Connect**<sup>™</sup>

Call X4Connect at 844-X4CNNCT (844-942-6628),  
M-F, 8am-8pm ET

Please see Important Safety Information on the last page and full Prescribing Information.

# Support for your patients on XOLREMDI

**X4Connect is a patient support program that offers a range of support services for your patients prescribed XOLREMDI.**

Once your patients are enrolled in X4Connect, our dedicated team is here to support them throughout their treatment journey.



## X4Connect Care Coordinators

- Investigate coverage and help navigate prior authorizations, appeals, and financial assistance options



## X4 Nurse Educators

- Provide education and available resources to patients and their caregivers about XOLREMDI and WHIM syndrome\*



## X4Connect Specialty Pharmacists

- Counsel patients on their XOLREMDI prescription

## X4Connect financial assistance programs

For eligible patients<sup>†</sup> we provide:

- **Copay Assistance:** helps patients with commercial or private insurance pay as little as \$0 for XOLREMDI up to a maximum annual limit
- **Quick Start Program:** helps patients access therapy in the event of an insurance-related delay
- **Bridge Program:** helps patients continue to receive therapy in the event of a coverage interruption
- **Patient Assistance Program:** helps patients who are uninsured or underinsured obtain access to XOLREMDI at no cost

## Additional resources<sup>‡</sup>



### Letter of Medical Necessity Template

A customizable sample letter that may help you with the prior authorization process for XOLREMDI.



### Letter of Appeal Template

A customizable sample letter for use during the appeals process for XOLREMDI if an appeal is necessary.



### X4Connect Patient Guide

Education on X4Connect program offerings for patients prescribed XOLREMDI.

\*X4 Nurse Educators are employed by X4. Nurse Educators do not offer medical advice and do not replace discussions with the patient's physician.

<sup>†</sup>Terms and conditions apply to all financial support options. X4 reserves the right to modify or discontinue these programs at any time. Full terms and conditions provided prior to enrollment.

<sup>‡</sup>Resources may be downloaded at [www.xolremdihcp.com](http://www.xolremdihcp.com).

Please see **Important Safety Information on the last page** and **full Prescribing Information**.

 **XOLREMDI**<sup>®</sup>  
(mavorixafor) capsules

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATION

XOLREMDI is contraindicated with drugs highly dependent on CYP2D6 for clearance.

### WARNINGS AND PRECAUTIONS

**Embryo-Fetal Toxicity:** Based on its mechanism of action, XOLREMDI is expected to cause fetal harm. Verify pregnancy status of female patients of reproductive potential prior to starting XOLREMDI. Advise females of reproductive potential to use effective contraception during treatment with XOLREMDI and for three weeks after the final dose.

**QTc Interval Prolongation:** XOLREMDI causes concentration-dependent QTc prolongation. Correct any modifiable risk factors for QTc prolongation, assess QTc at baseline, and monitor QTc during treatment as clinically indicated in patients with risk factors for QTc prolongation or receiving concomitant medications that increase XOLREMDI exposure and/or drugs with a known potential to prolong the QTc interval. Dose reduction or discontinuation of XOLREMDI may be required.

### ADVERSE REACTIONS

The most common adverse reactions (in >10% patients and more frequently reported than placebo) were thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting, and dizziness.

### DRUG-DRUG INTERACTIONS

Avoid co-administration of XOLREMDI and strong CYP3A4 inducers. Reduce XOLREMDI daily dosage to 200 mg when administered with strong CYP3A4 inhibitors. Monitor more frequently for adverse reactions associated with an increase in exposure of XOLREMDI when used concomitantly with moderate CYP3A4 inhibitors or P-gp inhibitors and reduce XOLREMDI daily dosage if necessary.

### USE IN SPECIFIC POPULATIONS

Advise females that breastfeeding is not recommended during treatment with XOLREMDI and for three weeks after the final dose.

The safety and effectiveness of XOLREMDI have not been established in pediatric patients younger than 12 years of age.

XOLREMDI is not recommended in patients with severe renal impairment, end-stage renal disease, or moderate to severe hepatic impairment.

To report suspected adverse reactions, contact X4 Pharmaceuticals at 1-866-MED-X4MI (1-866-633-9464) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see the full Prescribing Information for XOLREMDI.**



XOLREMDI® is a registered United States trademark of X4 Pharmaceuticals, Inc. X4Connect, X4 Pharmaceuticals, X4, and associated logos are trademarks of X4 Pharmaceuticals, Inc.  
© 2024 X4 Pharmaceuticals, Inc. All rights reserved. X4NM-US-001-2400006 (v3.0) October 2024

